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Abstract: Congenital cataracts are the prime cause for irreversible blindness in children. The global
incidence of congenital cataract is 2.2–13.6 per 10,000 births, with the highest prevalence in Asia.
Nearly half of the congenital cataracts are of familial nature, with a predominant autosomal dominant
pattern of inheritance. Over 38 of the 45 mapped loci for isolated congenital or infantile cataracts
have been associated with a mutation in a specific gene. The clinical and genetic heterogeneity of
congenital cataracts makes the molecular diagnosis a bit of a complicated task. Hence, whole exome
sequencing (WES) was utilized to concurrently screen all known cataract genes and to examine
novel candidate factors for a disease-causing mutation in probands from 11 pedigrees affected with
familial congenital cataracts. Analysis of the WES data for known cataract genes identified causative
mutations in six pedigrees (55%) in PAX6, FYCO1 (two variants), EPHA2, P3H2, TDRD7 and an
additional likely causative mutation in a novel gene NCOA6, which represents the first dominant
mutation in this gene. This study identifies a novel cataract gene not yet linked to human disease.
NCOA6 is a transcriptional coactivator that interacts with nuclear hormone receptors to enhance
their transcriptional activator function.
Keywords: congenital cataract; WES; FYCO1; PAX6; EPHA2; P3H2; TDRD7; NCOA6; hearing and
speech impairment; genetic heterogeneity; clinical heterogeneity
1. Introduction
Congenital cataracts (CC) are the leading cause of significant vision loss, accounting for
one-third of childhood blindness globally. The global incidence of congenital cataracts ranges
from 2.2–13.6 per 10,000 children, with the highest prevalence being estimated in Asia (7.43/10,000) [1].
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While 50% are of the hereditary nature is autosomal-dominant with complete penetrance,
autosomal recessive or X-linked types are rare. Cataracts can lead to permanent blindness by
interfering with the sharp focus of light on the retina, ensuing in a failure to establish appropriate
visual cortical synaptic connections with the retina. Despite the advancement in surgical management
and efficient visual rehabilitation, prompt early diagnosis is important to ensure visual outcome in
cataract surgeries to prevent blindness. Classical linkage and candidate gene analyses have established
the underlying genetic heterogeneity in congenital cataracts, which reports at least 38 associated
genes and 45 mapped loci so far [2]. However, there are more than 100 genes that are known to be
causative of either syndromic or non-syndromic CCs with intrafamilial and interfamilial variability
as reported in the Catmap database (http://cat-map.wustl.edu/). In a recent review on guide to
suspect the genetic basis of cataractogenesis, the authors have categorized the genes based on the
phenotypes reported in the literature as syndromic cataract (104 genes), genes implicated in syndromes
but with reports of only congenital cataracts (8 genes), only cataract causing genes (non-syndromic)
(34 genes) and genes that are known to cause cataract along with other eye anomalies (11 genes) [3].
Such classification aids in the analysis of molecular basis of congenital cataract as it gives a clue to
sort out the genes based on phenotypes and such classifications are helpful only if complete clinical
documentation of the patients is known. The consequence of an untreated congenital cataract leads
to an irreversible neurophysiological changes and sensory deprivation amblyopia with associated
outcomes of strabismus and nystagmus [4]. It is well known that the best outcome is documented on
congenital cataract surgery and optical corrections done before 6-8 weeks of age, thus emphasizing
good ophthalmic examination combined with multi-disciplinary team work to achieve the best possible
visual outcomes [4,5]. Early diagnosis is often a daunting task due to the numerous differences in
an infant eye compared to an adult. And often children with cataract are microophthalmic with
hypoplastic and vascular iris and may exhibit microcoria with immature trabecular meshwork and a
shallow anterior chamber with lack of rigid sclera [6]. Thus, prompt diagnosis of congenital cataract
and knowing its molecular basis not only enables to achieve optimum visual outcome but aids in
further management of the secondary disorders caused during the treatment for the primary disease [4].
The conventional candidate gene screening approach offers a limited scope for genetic diagnosis in
clinical practice. Hence, whole-exome sequencing (WES) has recently been successfully applied in
mapping disease-causing genes and mutations for Mendelian diseases and tumors. Employing exome
capture chips followed by next-generation sequencing comprehensively explores the potential structural
or functional variants in the exome. This study therefore aims to establish the molecular basis of
congenital cataracts in registered families (n = 11) through the whole-exome sequencing technique.
The implementation of next-generation sequencing (NGS) technologies in diagnostic genetic testing
has led to the rapid identification of pathogenic mutations in familial cases of inherited CCs. In this
study, we adopted whole-exome sequencing (WES) in probands of 11 cohorts representing clinically
diverse phenotypes of congenital cataracts. We could identify putative disease-causing variants that
enable a genetic diagnosis in 55% of the cases. Further, it is noted that autosomal recessive forms
(9/11) of cataracts do exist in South India in view of the social practice of consanguineous marriages.
The identified mutation spectrum included novel variants of already known candidates of CCs and a
novel potential candidate gene. Unresolved cases might be instrumental towards the identification of
novel disease-associated genes.
2. Results
2.1. Clinical Documentation and Pattern of Inheritance
In the present study, we analyzed 11 families for whole-exome sequencing based on sample
availability. Six families were resolved, marking the success rate as 55%. The complete clinical
documentation of the resolved six families are as detailed in Table 1. An autosomal-recessive pattern of
inheritance is observed in the majority of the recruited families, followed by an autosomal-dominant
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pattern of inheritance. Most of the probands and affected family members had a visual acuity of either
6/60 or less (Table 1).
2.2. Gene Mutation Identification From Whole-Exome Sequencing and Validation Through Sanger Sequencing
DNA samples of 11 probands were sequenced with NextSeq500 with an average of 39,000 variants
obtained through WES. The mean coverage was 200× with 88% of reads > 30×. Annotation of the
raw seqeunce data, variant calling, filtering and analysis were done as described in the methods.
The whole-exome data were sorted and filtered based on biological context and pathogenicity and
homozygosity/heterozygosity (based on the pattern of inheritance in each family), which led to the
identification of a novel mutation in known cataract genes, as well as some novel genes not yet associated
with congenital cataracts (Table 2). The mutations were analyzed using different in silico prediction
tools. Missense mutations were analyzed using Proven, SIFT, POLYPHEN-2, Mutation Accessor,
Panther and I-Mutant, while other mutations, including missense, were also analyzed using Mutation
taster, PhyloP and PhastCons, scores to show the conserved nature of the nucleotide across species.
The scores of individual variations identified in this study are validated and classified according to
ACMG criteria as detailed in Table 2.
2.3. Congenital Cataract Families Resolved for Genetic Mutations Using WES
Initial candidate gene screening of eight selected genes (based on the frequency of mutation
reported in the literature) in 11 congenital cataract probands did not reveal any mutations,
but only synonymous sequence variations (SNPs) were documented. The subsequent adoption
of next-generation sequencing facilitated a successful molecular dissection in 55% of the families
investigated with congenital cataracts. Out of 11 families studied, five cases were shown to have
novel putative disease-causing variants and one with an already known mutation. This study also
documented mutations in a novel gene, NCOA6, to be a putative gene for syndromial congenital
cataracts and associated hearing and speech impairments. The mutations documented in cases with
congenital cataracts are summarized as follows.
2.4. Family Code: DKEC4
Family history revealed an autosomal recessive mode of inheritance (Figure 1A), as both the
parents were unaffected, and there was one affected member in the second generation, a distant
relative (grandfather’s brother) of the proband, with similar congenital cataracts and was also reported
to be infertile by the grandmother. The proband depicted posterior polar cataracts (Figure 1B,C),
and other abnormalities were detected upon either an ophthalmologic or general physical examination
(specifically, ocular movements were full, conjunctivae were clear and the anterior chambers looked
normal). The WES analysis identified a novel homozygous mutation in the gene TDRD7, the deletion
of the last nucleotide A of codon 1004 (AAA, coding for lysine) that resulted in a frame shift mutation,
which subsequently introduced a premature stop codon in exon #16 (c.3012 del; p.Val1005Tyrfs*4)
(Figure 1D,I). This is a novel mutation that probably causes autosomal recessive cataracts in this
family. Bidirectional sequencing of exon 16 of the TDRD7 gene of the proband (IV.1) confirmed the
homozygous deletion at position c.3012. This deletion neither creates nor deletes any restriction site;
hence, all the available family members were checked through PCR-based sequencing of exon 16 of
the gene TDRD7, and all the unaffected family members were heterozygous carriers of the deletion
(Figure 1E–G). Insilico analysis using varsome shows this null variant (frame-shift), in gene TDRD7,
for which loss-of-function is a known mechanism of disease (gene has 6 pathogenic LOF variants and
LOF Z-Score = 4.41 is greater than 0.7), associated with Cataract, thus this variant is categorized as
pathogenic based on ACMG criteria on the following conditions, PVS1 (null variant), PM2 (variant not
found in gnomAD exomes and genomes), PP3 (pathogenic computational predictions). This mutation
was also cross-checked in unrelated control subjects (n = 100) of the same ethnicity, screened through
PCR-based direct sequencing and found to be absent (data not shown).
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Table 2. Summary of the genetic findings in in resolved Congenital cataract families.
Family-ID POI Consanguinity Zygosity Gene Variant Genomic Co-Ordinate Variant Identified RS ID and Frequency ACMG Criteria Solved Cases





reported before PATH S
C343 AD N HET PAX6 chr11-31823275-C-A PAX6(NM_001310158.2)c.233G > T (p.Gly78Val)
rs121907920-No frequency
reported LP S
CCE13 AR Y HOM EPHA2 chr1-16474911-C-T EPHA2(NM_004431.5):c.785G > A (p.Cys262Tyr)
NA-Novel variant not
reported before VUS S





reported before PATH S
ACR12 AR Y HOM FYCO1 chr3-46007891-G-A FYCO1(NM_024513.4):c.2935C > T (p.Gln979Ter)
NA-Novel variant not
reported before PATH S
BCC23 ND (PH)





ISB Kaviar3-0.0000257 VUS S
Y HET NCOA6 chr20-33338208-C-T NCOA6(NM_014071.5):c.1790G > A (p.Gly597Asp) rs1461340387-gnomAD-0.0000119 LB PS
Summary of the genetic findings in this study. POI—Pattern of Inheritance, ND—not determined, AR—autosomal recessive, AD—autosomal dominant, PH—Phenotypic Heterogeneity,
Y—Yes, N—No, HET—heterozygote, HOM—homozygote, NA—Not Applicable, ACMG American College of Medical Genetics, PATH—pathogenic, LP—Likely pathogenic, VUS—Variant
of uncertain significance, LB—Likely Benign, S solved, PS plausibly solved.
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Figure 1. The pedigree of DKEC4 (A). Eye picture of the proband’s (IV:1) right eye (B) and left eye
(C) depicting posterior subcapsular cataracts. Partial sequence chromatogram of the DKEC4 family
members, TDRD7 exon 16, depicting a homozygous mutation (c.3012 del; p.Val1005Tyrfs*4) in the
proband ((D)—IV:1). Other family members: mother ((E)—III:4), father ((F)—III:3) and grandmother
((G)—II:7) were heterozygous for this variant control subject (H), showing a wildtype sequence. Site of
mutation marked by an arrow. Mutational consequence leading to frame shift (in red) compared with
wildtype sequence (in green) (I). Amino acid sequence alignment of human TDRD7 and orthologs from
other species, showing a conservation of p.V10005 (encircled in red) (J). Divergent amino acid residues
are shaded in a white color background.
2.5. Family Code: C343
This is a retrospective case documented to have anterior polar cataracts with microcornea.
Family history revealed an autosomal dominant mode of inheritance (Figure 2A); multiple relatives of
the probands with similar phenotypes were documented. The WES analysis led to the identification of a
G>T transversion in exon #7 of the PAX6 gene, resulting in a missense mutation (c.233 G>T; p.Gly78Val)
(Figure 2B–D). This mutation deletes a restriction site for the enzyme, NlaIV; a Restriction Fragment
Length Polymorphism (RFLP) analysis among available family members indicated segregation of the
mutation among the affected family members (Figure 2G) but its absence in 120 ethnically matched
control subjects (data not shown). Both the nucleotide (which is evident by PhyloP (score 6.014) and
PhastCons (score 1)) and the amino acid (which is evident by a high score in PANTHER—1037) are
highly conserved across species (considering 12 species, up to Caenorhabditis elegans) (Figure 2H).
In-silico tools predict this variation to be pathogenic (Provean, −7.35; SIFT, 0; POLYPHEN2, 1; mutation
assessor, 3.78 and mutation taster, 1) (Grantham dist: 109 (0–215)). A Mutpred analysis also revealed it
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to be a deleterious mutation, with a probability of 0.951, loss of disorder (p = 0.0529), gain of molecular
recognition features (MoRF) binding (p = 0.0751), loss of glycosylation at S79 (p = 0.1159), loss of
phosphorylation at S79 (p= 0.1323) and loss of catalytic residue at T77 (p= 0.1757). Homology modeling
of the mutant and wildtype proteins revealed that mutated residue alters the exposure of neighboring
amino acids, which might affect the protein interaction with its downstream targets (Figure 2E,F).
Varsome analysis revealed that this variant as likely Pathogenic based on ACMG criteria—Hot-spot
of length 51 base-pairs has 14 non-VUS missense/in-frame variants (14 pathogenic and 0 benign),
pathogenicity= 100.0%, qualifies as hot-spot. Furthermore, 187 out of 199 non-VUS missense variants in
gene PAX6 are pathogenic = 94.0% which is more than threshold of 51.0%, and 418 out of 507 clinically
reported variants in gene PAX6 are pathogenic = 82.4% which is more than threshold of 12.0%.
Clinvar also categorizes this variant as pathogenic based on previous reports. Thus this variant is
categorized as pathogenic based on ACMG criteria on PM1 (hot spot of disease causing variations),
PM2 (variant not found in gnomAD exomes and genomes) and PP5 (based on clinvar classification as
pathogenic based on two submissions).
2.6. Family Code: CCE13
The proband had bilateral lamellar cataracts with microcornea and nystagmus with an
autosomal-recessive pattern of inheritance (Figure 3A). He had an affected sister with similar complaints
of nystagmus, who, upon clinical investigations, revealed lamellar cataracts with microcornea.
A G > A transition was observed in exon #3 of EPHA2, resulting in a novel missense mutation (TAC)
(c.785G > A; p.Cys262Tyr) (Figure 3B–D) that creates a restriction site for the enzyme RsaI. A RFLP
analysis performed among family members revealed the affected sibling as homozygous, while the
mother was a carrier of this mutation (Figure 3E) and was found to segregate among the affected
family members. Both the amino acid residue and the nucleotide are highly conserved across species
(considering 11 species up to Platypus) (which is evident by PhyloP (score 6.014) and PhastCons
(score 1)) (Figure 3F). In-silico tools predict this variation to be pathogenic (PROVEAN, −8.84; SIFT, 0;
POLYPHEN2, 0.658; mutation assessor, 3.755; and mutation taster, 1) (Grantham dist: 194 (0–215)).
Homology modeling of the wildtype and mutant proteins depict alterations in the secondary structure
leading to change in its overall structure, which might affect its function (Figure 3G,H). This variant is
categorized as variant of uncertain significance based on ACMG criteria on PM2 (variant not found in
gnomAD exomes and genomes) and PP3 (pathogenic computational verdict based on 12 pathogenic
predictions) as well as BP1 supporting (29 out of 40 non-VUS missense variants in gene EPHA2 are
benign = 72.5% which is more than threshold of 51.0%, and 75 out of 135 clinically reported variants in
gene EPHA2 are benign = 55.6% which is more than threshold of 24.0%.).
2.7. Family Code: CCE27
The proband had bilateral total patchy cataract of the autosomal recessive pattern of inheritance
type (Figure 4A). The proband had an affected sister with similar complaints, who, upon clinical
investigation, revealed total cataracts. The mother had a milder cataract phenotype expressed in her
late-teen ages. A novel homozygous mutation in the gene P3H2 (duplication of nucleotide G) that
affects the second nucleotide of codon #473, GAA (glutamine), resulted in a frame-shift mutation,
which, subsequently, introduced a premature stop codon in exon #9 (c.1417 dup; p.Glu473Glyfs*19)
(Figure 4B–E). This is a novel mutation identified to cause congenital cataracts that segregates among
the affected family members. The proband’s mother, being a carrier, had a milder phenotype (probably
due to haplo insufficiency) compared to her affected daughters. This mutation deletes a restriction site
for the enzyme MmeI. The RFLP analysis of this mutation among the family members revealed that
the affected sibling is homozygous, while both the mother and father were carriers for this mutation
(Figure 4D). This duplicated nucleotide is highly conserved across species (which is evident by PhyloP
(score 3.016) and PhastCons (score 1)). In-silico tools predict this variation to be pathogenic (mutation
taster, 1). About one-third of the amino acid residues are lost, which includes the loss of several
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sites, such as the Fe2OG dioxygenase domain (557–671): 705–708, a motif that prevents secretion
from the endoplasmic reticulum (ER); an active site of the enzyme 662; a carbohydrate attachment
site 549 (N-linked GlcNac) and iron-binding sites (580, 582 and 652). Hence, the mutated protein is
nonfunctional; however, there are possibilities of a nonsense-mediated decay of the transcript as well.
This variant is categorized as pathogenic based on ACMG criteria on PVS1 (Null variant (frame-shift),
in gene P3H2, for which loss-of-function is a known mechanism of disease (gene has 11 pathogenic
LOF variants and LOF Z-Score = 0.771 is greater than 0.7), associated with Myopia, high, with cataract
and vitreoretinal degeneration.) and PM2 (variant not found in gnomAD exomes and genomes) as











Figure 2. Pedigree of C343 (A). Partial sequence chromatogram of C343 family members, PAX6 exon 7,
depicting a heterozygous mutation (c.233 G > T; p.G78V) in the proband’s father ((B), II:17) and control
subject (C). Mutant and wildtype peaks “T” and “G” are marked by an arrow. Missense mutation
(in red) compared with the wildtype sequence (in green) (D). Model structure representing wildtype (E)
versus mutant (F) PAX6. The mutated amino acid is highlighted in red, while its interacting amino acids
nearby are marked in a white and blue combination. The mutated amino acid hinders the exposure of
neighboring residues such as threonine at position 77 and tyrosine at position 75 and, also, alters other
interactions, which might affect its interaction with its downstream targets. RFLP analysis of the
mutation p.G78V in PAX6 (G), which shows co-segregation of the heterozygous mutation among
affected family members (C2 and C6-C9). Unaffected family members (C3-C5) and control (DKC192)
(C10) show complete digestion. C1—undigested PCR product. Amino acid sequence alignment of
human PAX6 and orthologs from other species (H), showing the conservation of p.G78 (encircled in
red). Divergent amino acid residues are shaded in a white background.
2.8. Family Code: ACR12
The proband had posterior cortical cataracts in his left eye (LE) and lamellar cataracts in his
right eye (RE) (Figure 5B,C), with an autosomal-recessive pattern of inheritance (Figure 5A). He had
an affected sister with similar complaints, who, upon clinical investigation, revealed a cataractous
phenotype. A novel homozygous nonsense mutation, viz., c.2935C > T; p.Gln979* in the FYCO1 gene,
was observed (Figure 5D–F). This mutation deletes a restriction site for the enzyme, Sbf1; co-segregation
of the same was confirmed by Sanger sequencing, as well as through RFLP. This novel truncation
mutation was found to co-seggregate among the affected individuals (Figure 5G). The mutated
nucleotide is highly conserved across species (which is evident by PhyloP (score 5.648) and PhastCons
(score 1)) (Figure 5H). The novel mutation, p.Gln979*, resides in the coiled coil domain of FYCO1,
leading to a loss of three critical domains (FYVE and GOLD), including the coiled domain of the
protein. Hence, this mutation is predicted to interfere with the intracellular transport of autophagocytic
vesicles from the perinuclear area to the periphery, thus leading to the accumulation of a large number
of vesicles and, thereby, causes a loss of lens transparency. In-silico tools predict this mutation to be
pathogenic (PROVEAN, −7.15 and mutation taster, 0.99). This variant is categorized as pathogenic
according to ACMG criteria based on PVS1 (Null variant (nonsense), in gene FYCO1, for which
loss-of-function is a known mechanism of disease (gene has 11 pathogenic LOF variants and LOF
Z-Score = 2.17 is greater than 0.7), associated with Cataract, autosomal recessive congenital 2.),
PM2 (variant not found in gnomAD exomes and genomes) and PP3 (pathogenic computational verdict
based on 5 pathogenic predictions).






Figure 3. Pedigree of CCE13 (A). Partial sequence chromatogram of the proband ((B), IV:1) and
control subject (C), EPHA2 exon 3, depicting a homozygous mutation (c.785G > A; p.Cys262Tyr).
Mutant and wildtype nucleotide peaks “A” and “G” marked by an arrow. Missense mutation (red)
compared with wildtype sequence (green) (D). RFLP analysis of the mutation p.C262Y in EPHA2
(E), which shows co-segregation of the homozygous mutation among affected family members (IV:1
and IV:2). Unaffected mother as the carrier (III:3). Control (DKC192) (CTRL) shows no digestion.
UD—undigested PCR Product. Amino acid sequence alignment of human EPHA2 and orthologs from
other species (F), showing conservation of p.C262 (encircled in red). Divergent amino acid residues are
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shaded in a white background. Model structure representing wildtype (G) and mutant (H) EPHA2.
The mutated amino acid site is marked in red, while its interacting amino acids at the neighborhood are
marked in a white and blue combination. The large physiochemical difference between cysteine and
tyrosine alters its interactions with neighboring amino acids, which changes the structural confirmation






Figure 4. Pedigree of CCE27 (A). Partial sequence chromatogram of the proband ((B), IV:1) and control
subject (C), P3H2 exon 9, depicting a homozygous mutation (c.1417 dup; p.Glu473Glyfs*19). Mutant and
wildtype peaks are marked by an arrow. RFLP analysis of the mutation p.Glu473Glyfs*19 in P3H2 (D),
which shows co-segregation among the affected family members (IV:1 and IV:2), while the parents are
carriers (III:1 and III:2). Control (DKC192) (CTRL) shows complete digestion. UD—undigested PCR
Product. The variation leading to frame shift mutation (red) compared with the wildtype sequence
(green) (E).
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(H) 
Figure 5. Pedigree of ACR12 (A). Eye picture of the proband (IV:1)—right eye (B) depicting posterior
cortical cataracts and left eye (C) depicting Lamellar cataracts. Partial sequence chromatograms of
the proband ((D), IV:1) and control subject (E), FYCO1 exon 8, depicting a homozygous mutation
(c.2935C > T; p.Gln979*). Mutant and wildtype nucleotide peaks “T” and “C” marked by an arrow.
Mutational consequence leading to truncation (in red) compared with the wildtype sequence (in green)
(F). RFLP analysis of the mutation p.Gln979* in FYCO1 (G), which shows co-segregation among
the affected family members (IV:1 and IV:2). Unaffected parents are carriers (III:3 and III:4).
Control (CTRL-DKC190) shows complete digestion. UD—undigested PCR product of the control
sample. Amino acid sequence alignment of human FYCO1 and orthologs from other species (H)
showing the conservation of p.Q979 (encircled in red).
2.9. Family Code: BCC23
The proband who is deaf and dumb had dense cortical cataracts in his LE and posterior subcapsular
cataracts in his RE (Figure 6B). He had two affected siblings, who had posterior subcapsular cataracts,
depicting an autosomal-recessive pattern of inheritance (Figure 6A), and both siblings were deaf and
dumb. The mother had mild blue dot opacities in both her eyes, while the father was unaffected.
Two possible variants were documented in WES to be causative in this family. One of the variants
occurred in the gene FYCO1 as an in-frame deletion of three base pairs, leading to a loss of a single
amino acid (c.4288_4290del; p.Glu1430del) (Figure 6C–E). This variant was homozygous in the two
affected siblings, and the unaffected proband’s father was a heterozygous carrier for this variant (data
not shown). The deleted amino acid residue is highly conserved across species (Figure 6F). The deleted
three nucleotides were conserved across species (PhyloP (scores 1.5, 4.301 and 5.18 values for individual
nucleotides in the order of deletion) and PhastCons (score 1 for all the three nucleotides)). This variant
was observed in the Gnom AD exome database (Formerly known as Exome Aggregation Consortium
(EXAC) database) in the Southern Indian population at a very low frequency (0.00002) (no homozygotes
observed) (Supplementary Table S1). This variant is categorized as variant of uncertain significance
based on ACMG criteria considering PM2 (GnomAD exomes homozygous allele count = 0 is less than
3 threshold for recessive gene FYCO1 (good gnomAD exomes coverage = 96.6).Variant not found in
gnomAD genomes (good gnomAD genomes coverage= 31.3)) and PM4 (inframe variant in gene FYCO1
which is not in the repeat regions) as well as PP3 supporting (pathogenic computational prediction).
A heterozygous variant in the gene NCOA6 leading to a missense mutation (c.1790G > A;
p.Gly597Asp) was observed in the proband’s sample (Figure 6G–I). This mutation deletes a restriction
site for the enzyme RsaI. A RFLP analysis revealed that both the affected siblings with similar
phenotypes (both were deaf and dumb) had this heterozygous variant but not in the unaffected
father (Figure 6J). We could not analyze it in the mother, as it was a retrospective case. In-silico tools
predicted the NCOA6 variation to be pathogenic (PROVEAN, −1.52; SIFT, 0.008; POLYPHEN2, 0.949;
mutation assessor, 1.955 and mutation taster, 1). The mutated nucleotide is highly conserved across
species (which is evident by PhyloP (score 4.321), PhastCons (score 1) and Panther (which is evident by
a high PANTHER score of 750) (Figure 6K). This variant was observed in the Genome Aggregation
Database (gnomAD exomes) in the Southern Indian population at a very low frequency (0.00009) (no
homozygotes observed) (Supplementary Table S2). Some of the in-silico tools predicted this variant to
be deleterious and probably damaging. However, this variant is categorized as likely benign based on
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ACMG criteria on PM2 (GnomAD exomes allele count = 3 is less than 5 threshold for gene NCOA6
(good gnomAD exomes coverage = 60.5). Variant not found in gnomAD genomes (good gnomAD
genomes coverage = 28.3), BP1 supporting (17 out of 17 non-VUS missense variants in gene NCOA6
are benign = 100.0% which is more than threshold of 51.0%, and 35 out of 35 clinically reported variants
in gene NCOA6 are benign = 100.0% which is more than threshold of 24.0%.) and BP4 supporting
(6 pathogenic prediction and 7 benign computational prediction). A mutpred analysis revealed that
this had less probability for being deleterious (p = 0.207), whereas the same tool predicted that this
mutation might cause a loss of MoRF binding (p = 0.0575), loss of catalytic residue at A596 (p = 0.1278),
gain of solvent accessibility (p = 0.1583), loss of glycosylation at S599 (p = 0.2023) and gain of relative
solvent accessibility (p = 0.2363). The FYCO1 variant (c.4288_4290del; p.Glu1430del) is also predicted
to be pathogenic (PROVEAN, −7.62 and mutation taster, 0.99), with the loss of the critical domain
GOLD. However based on previous studies, the NCOA6 variant could act as a modifier along with the
FYCO1 variant and could be the plausible cause of the syndromic cataract reported in the family.
= 31.3)) and PM4 (inframe variant in gene FYCO1 which is not in the repeat regions) as well as PP3 
















Figure 6. Pedigree of BCC23 (A). Clinical phenotype of probands (IV:8): right eye depicting posterior
subcapsular cataracts (B) upon retro-illumination. Partial sequence chromatogram of BCC23 family
members, FYCO1 exon 17, depicting a homozygous mutation (c.4288_4290del; ∆E1430) in the proband’s
brother (IV:10) (C), and control subject (D) showing a wildtype sequence. Site of mutation was marked
by an arrow. The mutation leads to an in-frame deletion of a single amino acid (marked in red)
compared with the wildtype sequence (marked in green) (E). Amino acid sequence alignment of
human FYCO1 and orthologs from other species (F), showing a conservation of p.E1430 (encircled
in red). Partial sequence chromatograms (reverse) of the proband’s affected brother ((G), IV:10) and
control subject (H), NCOA6 exon 9, depicting a homozygous mutation (c.1790G > A; p.Gly597Asp).
Mutant and wildtype peaks “T” and “C” marked by an arrow. Missense mutation (marked in red)
compared with the wildtype sequence (marked in green) (I). RFLP analysis (J) of the variant allele
p.Gly597Asp in NCOA6, which shows co-segregation among the affected family members (IV:9 and
IV:10). Unaffected father (III:6) and control (CTRL-DKC190) shows complete digestion, indicating a
wildtype sequence. UD—undigested PCR product. Amino acid sequence alignment of human NCOA6
and orthologs from other species, showing a conservation of p.G596 (encircled in red). Divergent amino
acid residues are shaded in a white background (K).
3. Discussion
Congenital/pediatric cataracts is the leading cause of treatable childhood blindness globally.
Congenital cataract affects the quality of vision, as it hinders the transmission of light to the retina during
the critical period of visual development, which may lead to irreversible blindness. Earlier studies
have reported the difficulties in the prognosis/early diagnosis of congenital cataract, as this is crucial
in achieving better treatment outcome, A recent study has shown that only fewer cases (less than
50%) requiring cataract surgery under the age of 3 years of age were referred before 9 weeks of age,
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and emphasizes early diagnosis requires skilled professionals for a definite diagnosis [7]. This prompts
the necessity for early diagnosis and timely clinical intervention to avoid blindness or severe visual
impairment. Recent meta-analysis and systematic reviews indicate that south Asia has the largest
prevalence (7.43/10,000) of congenital cataract [1].
In the present study, a candidate gene screening panel consisting of eight genes in 11 families
with congenital cataracts revealed no putative mutations in any of the families. The major limitation
in this approach is that screening of all the reported 40 genes involved in cataractogenesis is not
only time-consuming but laborious as well. Hence, alternative rapid approaches as either panel
sequencing or whole-exome sequencing are being adopted as the method of choice to detect the
causative mutations underlying cataracts. In this study, screening through whole-exome sequencing
was adopted in 11 families short-listed based on the size of the kindred and the maximum number
of available samples. Pedigrees registered through prospective (n = 6), as well as retrospective,
studies (n = 5) were taken up for whole-exome sequencing. This method was promising towards
characterizing the molecular basis in at least six out of the 11 families screened (already screened for
eight genes), which is about 55 percent compared to the approach by candidate gene screening.
However, the limitations in our study includes some of the retrospective cases have limited
samples and not extensive clinical documentations were available, which halted further analysis.
Furthermore, there are always possibility of the role of non-coding genes and epigenetic mechanism
which could play a crucial role in certain cases, where the causative mechanism is yet to be identified.
A recent review on management of pediatric cataracts has reviewed the effect of early and late
post-operative complications on the better visual outcome, suggesting recommendations on operational
procedures in children less than 6 years and suggest hydrophobic foldable acrylic posterior chamber
intraocular lens (PCIOL) to lower the post-operative inflammation. They have also suggested that timely
detection aids in the proper long-term management addressing the post-operative visual rehabilitation
such as refractive correction treatment of concomitant amblyopia and bifocal correction [8]. With the
advancement in molecular diagnosis, clinical prognosis can be made appropriately and on time for
better management of the disorder. In our study, one of the family (DKEC4), the family members were
informed about the genetic condition and was suggested if any new born in their extended family
could do the genetic test for an early prognosis and management of the disorder for a better visual
outcome and they have enrolled for special tests. Recently one of the newborn in their extended
family members was tested positive, and was under continuous management, which aid in the timely
management of the disorder for a better outcome. Thus knowing the disease variant aids in the future
management of the disease in the extended family members, especially like our cohort (similar to
all Asian population), where in consanguineous marriages are still in practice leading to successive
disease phenotypes in the future offspring’s.
The spectrum of mutations identified varied as two-frame shift mutations in P3H2 and TDRD7;
one nonsense mutation in FYCO1 and three missense mutations in NCOA6, PAX6 and EPHA2.
One in-frame deletion was also detected in FYCO1. The scope of whole-exome sequencing lies in the
possibility of the identification of novel genes; accordingly, in the present study, we documented a
novel gene, NCOA6, with a missense variation that is likely to be the molecular lesion underlying the
posterior capsular cataracts in the family BCC23; this variant is also associated with the deaf and dumb
phenotype as well.
As per the literature, the success rate of mutation detection was enhanced by targeted panel
sequencing and whole-exome sequencing. Employing targeted panel sequencing comprised of 34 genes,
Sun et al. (2014) [9] identified putative disease-causing variants in 50% of the families screened (nine
out of 18 families), while it was 70% (46 cases comprised of both sporadic and familial origins) by
screening 32 cataracts-associated genes through panel sequencing [10]. Zhai et al. (2017) [11] performed
a panel sequencing of 54 cataracts-associated genes in 27 Han Chinese congenital cataracts families
and was successful in detecting mutations in 17 out of 27 families studied. Few of the recent studies
also focused on the genetic basis of sporadic cases. Li et al. (2016) [12] identified ~26% putative
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disease-causing variants (19 out of 74 patients) in sporadic congenital cataracts of the Han Chinese
population through the panel sequencing of 61 lens-related genes.
In the present study, a four-generation pedigree with the skipping of a cataracts phenotype was
documented. Candidate gene screening of eight genes in this family did not reveal any putative
disease-causing variants. Whole-exome sequencing of the proband revealed a homozygous frame shift
mutation, viz., p.Val1005Tyrfs*4 in the gene TDRD7. An analysis of the family members revealed that
the proband’s parents and grandmother were carriers of this mutation; however, the other affected
family member documented in the pedigree was not available for the study. The same mutation is absent
in 120 ethnically matched control subjects, as verified by PCR-based direct sequencing. The mutation
leads to the loss of the Tudor domain, which is crucial for its function. However, the frameshift
occurs in exon no. 16 before the last exon, so there are possibilities for a nonsense-mediated decay of
the transcripts.
TDRD7 is a Tudor domain containing a RNA-binding protein, which forms part of the RNA
granules found to regulate cytoskeletal dynamics, movement of the cytocentrum and regulation
and transportation of mRNA. They are expressed in lens fiber cells and male germ cells and are
known to regulate the post-transcriptional modification of critical genes involved in lens development
and spermatogenesis [13,14]. RNA granules determine the fate of a mRNA and are present in the
form of processing bodies (PB) or stress granules (SG) in lower eukaryotes [15]. Lens fiber cells are
functionally analogous to neurons and germ cells like sperm in several aspects, such as elongated
nature, transcriptionally inactive and maintaining polarity. Recent studies have indicated that lens fiber
cells also possess RNA granule-mediated post-transcriptional regulatory functions for its specialized
morphology [13]. The mutation observed in this study (p.Val1005Tyrfs*4) results in the loss of less
than 10% of the protein, leading to a slightly truncated protein; one of the critical Tudor domains is
lost due to this mutation, which makes it nonfunctional, thereby causing congenital cataracts in the
proband. However, there are also possibilities for a nonsense-mediated decay of the mutant transcript.
In the present study, the family C343 was documented to have a mutation in PAX6 (p.Gly78Val).
About 472 unique PAX6 variants have been reported to cause a spectrum of eye diseases and other
anomalies (http://lsdb.hgu.mrc.ac.uk/home.php?select_db=PAX6). PAX6 mutations are known to
cause mainly Aniridia; however, other ocular anomalies, including microcornea, microphthalmia,
congenital cataracts, keratitis, ocular coloboma, Peter’s anomaly, Gillespie syndrome, morning glory
disc anomaly, foveal hypoplasia and optic nerve hypoplasia, have also been reported. This mutation in
PAX6 (G64V) is already reported to cause congenital cataracts with foveal hypoplasia [16]. The mutation
as either G78V or G64V based on the splice variant identified in the current study is in the paired
domain of PAX6 and causes autosomal-dominant congenital cataracts with microcornea in the kindred
C343. Two-thirds of the reported missense mutations occur in the paired domain and may thus alter the
binding specificity of some of the PAX6 targets [17]. Functional characterization of the paired domain
missense mutation reported variations in either DNA-binding activity or transactivation activity of
mutant PAX6 [18–20]. In general, the mutation in PAX6 disturbs the entire downstream signaling
cascade, leading to a spectrum of ocular phenotypes, as evidently documented in the literature,
in several families with unusual phenotypes, along with cataracts.
The family CCE13, a four-generation pedigree (retrospective case) with affected offspring
documented only in the fourth generation. Whole-exome sequencing analysis identified a novel
putative disease-causing variant in the gene EPHA2, p.Cys262Tyr, which co-segregated among the
affected individuals (IV:1 and IV:2) but was absent in the unaffected mother and 120 ethnically matched
control subjects. Precisely, to date, the EPHA2 mutation observed (C262Y) in the present study is
the first one to be documented in the cysteine-rich region. Homology modeling of wildtype and
mutant proteins revealed that the altered amino acid, tyrosine, affects the interactions with neighboring
amino acids, leading to conformational changes in the protein, making it dysfunctional. As per the
literature, only one family with a EPHA2 mutation has been documented to have persistent fetal
vasculature [21]. Persistent fetal vasculature (PFV) arises due to a failure in the regression of the hyaloid
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vasculature, which is one of the commonest causes of infantile cataracts. PFV is sometimes associated
with microcornea and might cause secondary glaucoma due to elevated IOP (intra-ocular pressure).
In the present study, the affected members of the family CCE13 are reported to have microcornea
and nystagmus, along with lamellar cataracts; however, for further investigations, the family is not
retrievable. A follow-up clinical study might answer several questions that might arise due to the
multifunctional role of EPHA2.
A retrospective case CCE27 of three-generation pedigree depicting intra-familial clinical
heterogeneity was documented in our earlier study. The mother had mild developmental cataracts,
while her two daughters had severe patchy and total cataracts since birth, and the father was
documented to have normal vision. Initial candidate gene screening did not reveal any putative
disease-causing mutations; when the proband’s sample was investigated through whole-exome
sequencing, a novel frame shift mutation in the gene P3H2, p.Glu473Glyfs*19 was identified.
P3H2 (Prolyl 3-hydroxylase) plays a critical role in collagen chain assembly, stability and crosslinking
by catalyzing the post-translational 3-hydroxylation of proline residues in collagen. Collagens are the
most abundant protein that constitutes up to about 30% of the total protein mass in mammals [22].
The present study documented a frame shift mutation, p.Glu473Glyfs*19, which resulted in the
loss of one-third of the amino acids, leading to a truncated protein. Some critical domains (Fe2OG
dioxygenase domain), active sites, signaling motifs and metal-binding sites necessary for the proper
function of the enzyme are eventually lost due to this mutation. This mutation is predicted to undergo
nonsense-mediated decay, and hence, loss of function of this gene could cause the cataract phenotype
in the family. However, in earlier reports, the heterozygous carriers were documented to be normal,
while, in the present study, a milder phenotype was documented in the heterozygous mother and is
subjective to further analysis.
Whole-exome sequencing analysis of the proband (ACR12) revealed a pathogenic mutation
in FYCO1, viz., p.Gln979*, which co-segregated with the affected individuals and was absent in
120 ethnically matched control subjects. As this mutation causes a premature stop codon, it might lead
to nonsense-mediated decay of the transcript. FYCO1 is a phosphatidylinositol-3-phosphate-binding
protein that functions like an adaptor, linking autophagosomes to microtubule plus-end-directed
molecular motors. FYCO1 consists of a central long-coiled coil region with a helical RUN domain at
its N-terminal, a FYVE domain, a LC3-interacting region and a GOLD domain at its C-terminal [23].
Fyco1 expression in a mouse starts at E8.5, which remains stable until E12.5, then doubles until E16.5
to P12, with an eventual decrease in expression during the early embryonic stages [24]. From their
observation, it is clear that the FYCO1 expression is high during secondary fiber cell differentiation,
which involves a denucleation process, thus substantiating its role in autophagy by clearing organelles.
The degradation of aggregated misfolded proteins through autophagy is essential for regulating
light scattering and lens transparency; any impairment in this process will lead to cataractogenesis.
On another retrospective case, BCC23, four-generation kindred presented with a milder cataract
phenotype as blue dot cataracts in the mother, whose children had severe cataracts phenotype,
besides also being deaf and dumb. This family depicted intrafamilial phenotypic variability even
within the same individual; the affected child’s LE had a dense cortical cataract, while the RE showed
a posterior subcapsular cataract. Whole-exome sequencing of the proband revealed an in-frame
deletion of a single amino acid in the FYCO1 gene (p.Glu1430del). This variant has been reported
in the ExAC browser in the South Asian population with a low allele frequency of 0.00024 with
no homozygotes reported. This mutation lies in the GOLD domain, which might interfere with its
function. However, the role of this variant in the pathogenesis of cataracts is unknown and needs to
be functionally analyzed to resolve its direct effect on the protein function or its indirect action as a
modifier. Two affected individuals, the proband’s brother and sister, were homozygous for this variant,
while their father was a heterozygous carrier.
A novel variant in the gene NCOA6 (p.Gly597Asp), hitherto not known to be linked with human
cataracts, was documented in this family. NCOA6 is a multifunctional protein, a ubiquitously expressed
Int. J. Mol. Sci. 2020, 21, 9569 19 of 23
coactivator of specific nuclear receptors and several other transcription factors [25]. NCOA6 is a large
protein consisting of 2063 amino acids, with two nuclear receptor boxes (containing the characteristic
LXXLL sequence), two transactivation domains, a dimerization region and an inhibitor region at the
C-terminal rich in serine, threonine and leucine (STL region). Previous studies targeting the knockout
of Ncoa6 resulted in embryonic lethality between E8.5 and E12.5 [26–29], which elucidates the crucial
role of Ncoa6 in embryonic development, cell survival and homeostasis. In general, coactivators of the
nuclear receptor play a crucial role in modifying the chromatin structure and directly interact with
components of Transcription factor II D (TFIID) basal transcription machinery [30].
The expression of the N-terminal nuclear receptor box of NCOA6 (that contains a LXXLL1 motif)
in postmitotic transgenic mouse lens fiber cells depicted impaired lens fiber cell differentiation and
denucleation, resulting in p53-dependent and independent apoptosis [31]. The N-terminal nuclear
receptor box acts in a dominant negative manner that abolishes the function of NCOA6, depicting a
series of lens fiber cell-specific differentiation defects, which includes the disruption of crystallin
expression, incomplete and prolonged apoptosis and the inhibition of denucleation in the lens fiber cells.
Defects such as persisting nuclei (karyolysis defects) were also observed in the lens-specific knockout
of Ncoa6. Further, the lens vesicle at E11.5 is normal, indicating that Ncoa6 may not be required either
at the initial stages of lens development or lens cell lineage specification. Furthermore, this knockout
mouse did not exhibit any morphologically detectable phenotype until three to four weeks of age [31].
In the present study, for the first time, a variation (Gly597Asp) was identified in NCOA6 associated
with human congenital cataracts, along with hearing and speech impairments. The alteration
of hydrophobic glycine with acidic aspartic acid might affect the contact sites between amino
acids, thereby leading to impaired structures with defects in the interactions with its targets.
Interestingly, a previous study on NCOA6 indicated that the amino acids 586−860 readily interact
with Thyroid hormone nuclear receptor α (TRα) and Thyroid hormone nuclear receptor β (TRβ)/
ligand-binding domain (LBD) [32]. TRα and TRβ are known to play a crucial role in ear development.
The variation G597D identified in the present study is in this region, though predicted to be benign
by some of the insilico tools, we speculate that this could be a modifier allele and affect downstream
targets. It is therefore tempting to speculate that the variation G597D might interfere with the
interaction between NCOA6 and TRα / TRβ, thereby causing hearing impairment in the affected
subjects. However further analysis through functional characterization of this specific variation both
in vitro and in vivo might elucidate the suggested mechanism. From the literature targeted NGS
approach with detailed clinical investigation has proven to be successful in underpinning the molecular
mechanism of cataractogenesis. We also emphasize that prognosis of known cataract mutations
in extended family members and their future generations could aid in the better management of
the disorder.
4. Materials and Methods
4.1. Patients and Families
Eleven families diagnosed with congenital cataracts were included in this study. Among them,
five were retrospective families recruited during 1998–2010. Clinical diagnosis was based on manual
examination by the physician in children and slit lamp examination for grownups and adult cooperative
patients. The study protocol was in accord with the ethical guidelines of the 1975 Declaration of Helsinki
and was approved by the Institutional Ethical Committee, Madras Medical College, Chennai (Approval
No. 29022013, dated 25th February 2013). Informed consent for genetic testing was sought and
obtained from all patients, parents and family members.
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4.2. DNA Extraction and Quantification
Genomic DNA was extracted from blood by standard extraction procedures (Phenol Chloroform and
Isoamylalcohol (PCI) method). DNA quantification was performed using the Nanodrop (Life technologies,
Darmstadt, Germany).
4.3. Whole-Exome Sequencing and In Silico Analysis
WES was performed in-house using Illumina NextSeq500; libraries were generated using Nextera
Rapid Capture Exome (Illumina) to generate 150-bp paired end reads. Alignment of sequence reads,
indexing of the reference genome, variant calling and annotation were done with a pipeline based
on Burrows-Wheeler Aligner (BWA) using Base Space Onsite (Illumina). Variants were annotated
using Alamut-Batch and visualized on Alamut Viewer 2.2 (Interactive Bio software, Rouen, France).
A filtering pipeline was established to identify the most likely disease-causing variant. The variants
are sorted out based on already known cataract genes listed in cat map database [33]. Since CCs are
rare in the population, only variants with a frequency below 1% were chosen. Frequencies of identified
variants were also cross-verified on Exome Sequencing Project (ESP) data and Exome Aggregation
Consortium (ExAC) data. Mutations that have been previously described to be disease-causing in the
Human Gene Mutation Database (HGMD) and literature were given the highest priority. The effects of
mutations that were described in the HGMD were further validated by reading published literature
reporting the variants, and only those variants that had convincing evidence were chosen. In addition,
protein truncation mutations such as nonsense and frame shift (insertions or deletions) were also
ranked higher in priority. Variants were categorized following standardized American College of
Medical Genetics (ACMG) criteria [34]. Variants were evaluated for the PP3 in-silico prediction (around
21 known insilico tools embedded in the database) criterion using predictions from Varsome [35].
4.4. Primer Design, PCR Amplification and Sanger Sequencing
To confirm the putative variants and their co-segregation among family members, primers were
designed using online tools and browsers (UCSC Genome browser, Ensemble) and were standardized
in gradient PCR. DNA samples of patients and their family members were used to amplify appropriate
gene fragments and sequenced commercially to identify mutations and their co-segregation. The list
of primers used in the current study for the confirmation of mutations observed were as given in
Supplementary Table S3. Direct sequencing was done at GATC, Konstanz, following the standard
procedures, and sequences were BLAST-aligned for homology and variations. All data relevant to the
study are included in the article or uploaded as supplementary information. The raw data that support
the findings of this study are also available from the corresponding author upon reasonable request.
5. Conclusions
In conclusion, the present study demonstrated the efficacy of NGS methods (whole-exome
sequencing) in the genetic diagnosis of inherited congenital cataracts. Whole-exome sequencing
(WES) was done on 11 families with congenital/childhood cataracts, and the success rate was 55%
(six out of 11 families screened). Four novel mutations were observed in already known candidate
genes (FYCO1, E979* (ACR12); ∆Q1430 (BCC23), EPHA2, C262Y; P3H2, Q473GfsX19 and TDRD7,
V1005YfsX4); one known mutation (G78V) in the PAX6 gene was also documented. A further analysis
of the WES data led to the identification of variation in novel gene (NCOA6, G597D) to be associated
with congenital cataract and hearing and speech impairment in BCC23 family, which requires further
functional validation. Furthermore, the present study also offers a lead scope for a subset of future
prospective studies that might aid in the dissection of molecular pathology of certain pathogenic gene
variants towards the prognosis and therapeutic intervention of congenital cataracts.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/24/
9569/s1. Table S1: Population frequency of the rare variant in the gene FYCO1(NM_024513.4):c.4288_4290del
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documented in family BCC23 (Source Genome Aggregation Database (gnomAD exomes), successor to ExAC
Database), Table S2: Population frequency of the rare variant in the gene NCOA6:c.1790G>A documented in
family BCC23 (Source Genome Aggregation Database (gnomAD exomes)), Table S3: Primers used to check the
co-segregation of putative variants documented in Whole exome sequencing.
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